GT Biopharma, Inc. (GTBP) earnings
GTBP earnings moved a median of +0.34% by the close. Quarterly and annual GTBP reports and results, each read against the price at its own news timestamp. Back to the GTBP overview →
23 measured GTBP earnings events.
Where these GTBP earnings landedvs 23 measured GTBP earnings reactions
| Middle 50% of GTBP earnings reactions | -8.22% to +3.60% |
|---|---|
| Median reaction (to close) | +0.34% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 GTBP earnings events with a measured close landed between -8.22% and +3.60%; 52% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q GT Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | +1.42% | +0.34% | |
| GT Biopharma Reports Second Quarter 2026 Financial Results | Press release | +1.42% | +0.34% | |
| Form 10-Q GT Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | -10.81% | -12.56% | |
| GT Biopharma Reports First Quarter 2026 Financial Results | Press release | -10.81% | -12.56% | |
| Form 10-Q/A GT Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -4.26% | -9.35% | |
| Form 10-Q/A GT Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -4.26% | -9.35% | |
| Form 10-K GT Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.67% | +0.95% | |
| Form 10-Q GT Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | -8.36% | -8.97% | |
| GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -4.00% | +23.60% | |
| Form 10-Q GT Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -10.95% | -8.22% | |
| GT Biopharma Reports Second Quarter 2025 Financial Results | Press release | -10.95% | -8.22% | |
| Form 10-Q GT Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.90% | +0.90% | |
| Form 10-K/A GT Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | — | +6.28% | |
| Form 10-K GT Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -7.31% | |
| Form 10-Q GT Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +4.10% | -0.34% | |
| GT Biopharma Reports Third Quarter 2024 Financial Results | Press release | +4.10% | -0.34% | |
| Form 10-Q GT Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | -2.61% | +3.04% | |
| GT Biopharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update | Press release | -2.61% | +3.04% | |
| Form 10-Q GT Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | +0.00% | +7.57% | |
| GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update | Press release | +0.00% | +7.57% | |
| Form 10-K GT Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | +0.00% | -0.68% | |
| Form 10-Q GT Biopharma, Inc. For: Sep 30 | SEC filing · Form 10-Q | +0.00% | +4.17% | |
| GT Biopharma Reports Third Quarter 2023 Financial Results | Press release | +0.00% | +4.17% |
Keep exploring
More GTBP: analyst actions → · SEC filings → · GTBP overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DURECT Corporation (DRRX) | 159 | +0.03% | 51% |
| Galmed Pharmaceuticals Ltd. - Ordinary Shares (GLMD) | 159 | -1.80% | 36% |
| ImmuCell Corporation (ICCC) | 159 | 0.00% | 42% |
| CollPlant Biotechnologies Ltd. - Ordinary Shares (CLGN) | 158 | -1.25% | 25% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.